|
|
|
|
|
by timr
4178 days ago
|
|
What they're describing here is an intensive selection process for resistance. It's debatably much more intensive than nature would ever perform: they're growing bacteria in the presence of various dilutions of the antibiotic, taking a sample of the culture, diluting it 100-fold, and repeating the selection many (~30) times. Then they look for any bugs that develop resistance. None were found. Even if you had a truly pathological patient (i.e. someone who was doing his level best to mis-use an antibiotic), it wouldn't come close to this level of selective pressure for antibiotic resistance. Moreover, there's a strong biochemical argument against resistance: the region that the antibiotic targets is highly conserved, which means that it's probably functionally necessary. The bug is therefore unlikely to evolve away from the threat. This is important, because it's that most likely avenue for antibiotic resistance, energetically speaking: it doesn't cost anything for an organism to mutate a weakly conserved gene, so they do it once, and pass it on to every subsequent generation with no penalty. The antibiotic is just a peptide, so in theory you could see some sort of specialized peptidase evolve from an existing gene...but the problem is that the bug would have to then carry around that gene and express it constantly (or even less likely: evolve a sensing system that allows for selective expression). It's a highly unlikely thing, and virtually impossible to maintain over multiple generations without constant selective pressure. Bacteria do not like to hold on to genes that they don't need. Nothing is impossible over evolutionary time, of course, but the researchers don't seem to be overstating their case here. |
|
However, that does not exclude the possibility of the bacterium acquiring a plasmid or phage carrying an enzyme that inactives teixobactin. This particular mode of acquiring antibiotic resistance is quite common.
Nevertheless, this finding does seem to be quite a big deal. A novel broad-spectum antibiotic where spontaneous resistance is unlikely is a pretty powerful addition to the pharmacopeia.